TAG:
pathology labs
New Business Helps Reduce Pathology Specimen ID Errors
By Joseph Burns | From the Volume XIX No. 17 – December 10, 2012 Issue
CEO SUMMARY: Prevention of diagnostic testing errors is getting more attention by both physicians and pathology labs because patients are less tolerant of potentially life-changing errors. Strand Diagnostics’ Know Error system is designed to reduce or eliminate errors involving tissue s…
OURLab Founder Lays Out New Business Strategy
By Joseph Burns | From the Volume XIX No. 16 – November 19, 2012 Issue
CEO SUMMARY: For OURLabs of Nashville, Tennessee, it was the host of changes in the lab testing marketplace that motivated it to go looking for a partner. Its recently-announced merger with OPKO Health, Inc., of Miami, Florida, creates opportunities for OURLab pathologists to do more in t…
More Medicare Auditors Are Targeting Clinical Labs
By Joseph Burns | From the Volume XIX No. 16 – November 19, 2012 Issue
CEO SUMMARY: For labs and all healthcare providers, the risk of an audit is growing because the number of auditors seeking overpayments is rising. In their efforts to eliminate waste and make the Medicare and state Medicaid programs more efficient, federal officials have introduced severa…
Louisiana Pathologists ‘Moonlight’ as Consultants
By Joseph Burns | From the Volume XIX No. 15 – October 29, 2012 Issue
CEO SUMMARY: Few independent pathology groups have developed robust laboratory consulting businesses. But adopting that strategy has brought important benefits to Delta Pathology Group, LLC, of Shreveport, Louisiana. Not only has providing lab consulting services to cash-strapped hospital…
Labs Have Questions about Prostate Biopsy Policy
By Joseph Burns | From the Volume XIX No. 13 – September 17, 2012 Issue
CEO SUMMARY: How will pathology laboratories respond to the publication of revised policies in how laboratories should file Medicare Part B claims for prostate biopsies? Not only will there be a sharp drop in the reimbursement paid for a 12-core prostate biopsy, but labs may be at increas…
Prostate Biopsy Claims Affected by Policy Change
By Joseph Burns | From the Volume XIX No. 12 – August 27, 2012 Issue
CEO SUMMARY: Quietly, with no fanfare and little advance public notice, the Medicare program is taking steps to change reimbursement policy for prostate biopsies. On August 7, 2012, Palmetto GBA adopted the new policy published on January 1, 2012, by the National Correct …
Lab Restructuring Moves Ahead in United Kingdom and Ireland
By Robert Michel | From the Volume XIX No. 8 – June 4, 2012 Issue
IT IS TOUGH TIMES FINANCIALLY for pathology and clinical laboratories in the British Isles. In both the nations of the United Kingdom and Ireland, the budget woes of the respective national governments are driving major changes in the organization and delivery of laboratory testing services. In the …
MD Self-Referral Issues Target of Utilization Study
By Robert Michel | From the Volume XIX No. 6 – April 23, 2012 Issue
CEO SUMMARY: When it comes to the in-office ancillary service (IOAS) exception to physician self-referral, the issue of in-clinic pathology services has become a hot potato. Publication in Health Affairs of a study of urologists’ self-referral of their patients for anatomic pathology se…
Medicare Extends 5010 Implementation for a Second Time, Effective July 1, 2012
By Robert Michel | From the Volume XIX No. 6 – April 23, 2012 Issue
FACED WITH THE FACT that many payers were not ready to implement the 5010 standard under the Health Insurance Portability and Affordability Act (HIPAA), on March 15, the federal Centers for Medicare & Medicaid Services (CMS) announced a second delay in enforcement of the standard…
Considering Full versus Partial Adoption of Digital Pathology
By Robert Michel | From the Volume XVIII No. 17 – December 19, 2011 Issue
CEO SUMMARY: Digital pathology is considered to be one of the more disruptive technologies now finding acceptance in anatomic pathology. Since founding Aperio Technologies, Inc., of Vista, California, in 1999, President Dirk G. Soenksen, M.S., M.B.A., has been in the forefront of this imp…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized